Side effects for both medications are similar, primarily gastrointestinal, and can usually be managed through gradual dose escalation and lifestyle adjustments
The percentage of participants experiencing vomiting is higher than what has been reported for the injectables, both in trials and real-world settings
DeLapp, APRN and Liz Vandyke Freer, PA-C and overseen by Dr
What Happens
Participants were randomized to increasing doses of once-weekly semaglutide or placebo
Nevertheless, as the simultaneous activation of GLP-1 and GIP receptors in preclinical models results in greater WL and glucose-lowering efficacy compared to activation of each receptor alone [38,39,40], the interest for the development of unimolecular GLP-1 and GIP RA was increased, despite that this additive effect in food intake and glycaemia was not observed in some acute clinical studies [41, 42]